Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7361787 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 1 month ago) | |
USRE44874 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 1 month ago) | |
US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(11 months from now) | |
US7439393 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(1 year, 23 days from now) | |
US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(8 years ago) | |
US7776895 | GLAXOSMITHKLINE | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(1 year, 7 months ago) | |
US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(11 months from now) | |
US8183257 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(1 year, 2 months from now) | |
US7439393 (Pediatric) | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(1 year, 6 months from now) | |
US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(3 years from now) | |
US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
US8511304 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Dec, 2027
(3 years from now) | |
US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(4 years from now) | |
US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(4 years from now) | |
US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) |
Anoro Ellipta is owned by Glaxosmithkline.
Anoro Ellipta contains Umeclidinium Bromide; Vilanterol Trifenatate.
Anoro Ellipta has a total of 25 drug patents out of which 4 drug patents have expired.
Expired drug patents of Anoro Ellipta are:
Anoro Ellipta was authorised for market use on 18 December, 2013.
Anoro Ellipta is available in powder;inhalation dosage forms.
Anoro Ellipta can be used as indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema., maintenance treatment of patients with chronic obstructive pulmonary disease (copd).
Drug patent challenges can be filed against Anoro Ellipta from 18 December, 2017.
The generics of Anoro Ellipta are possible to be released after 11 April, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 18, 2016 |
New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.; Mai...
Dosage: POWDER;INHALATION